We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years (IFM/DFCI2009)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01191060
Recruitment Status : Active, not recruiting
First Posted : August 30, 2010
Last Update Posted : January 5, 2018
Dana-Farber Cancer Institute
Celgene Corporation
Janssen-Cilag Ltd.
Information provided by (Responsible Party):
University Hospital, Toulouse